$1.60
-0.03 (-1.54%)
Open$1.63
Previous Close$1.63
Day High$1.64
Day Low$1.59
52W High$5.61
52W Low$1.17
Volume—
Avg Volume44.6K
Market Cap14.67M
P/E Ratio—
EPS$-3.04
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+2,436.3% upside
Current
$1.60
$1.60
Target
$40.58
$40.58
$25.27
$40.58 avg
$56.74
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 7.34M | 7.69M | 6.20M |
| Net Income | 836.8K | 704.4K | 655.3K |
| Profit Margin | 11.4% | 9.2% | 10.6% |
| EBITDA | 1.33M | 1.40M | 1.15M |
| Free Cash Flow | 524.0K | 541.1K | 340.9K |
| Rev Growth | +8.2% | -3.9% | -5.2% |
| Debt/Equity | 0.19 | 0.19 | 0.18 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |